In a Q&A, Glenn J. Hanna, MD (@HeadNeckMD) discussed: ✅ The ongoing development of micvotabart pelidotin 📊 The importance of biomarker-driven treatment approaches for HNSCC 🌟 And more! @DanaFarberNews Read his insights:

Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report, ranked as #3 in the nation and the only one top ranked in New England for 2025-26. Learn more: https://t.co/JOZgF0nBf7

⏰🚨👏ReACT1.0 #ASCO25 @HeadNeckMD @jdschoenfeld1 @MargalitMd @DrHaddadRobert 🌟 Ph2, stage I-III HPV+ OPC 🌟54-66Gy gross dz based on risk/DNA clearance 🌟30-54Gy elective 🌟~60%>95% clearance at wk 4-5 🌟2yr PFS 90% - 5 events (1 death): 3LRR, 4DM

Today at #ASCO25: @HeadNeckMD of @DanaFarber presents phase 2 data suggesting circulating HPV DNA can be a biomarker before & during treatment for HPV-positive oropharyngeal cancer to guide treatment intensity w/o compromising PFS survival in higher-risk pts.

Dr. @HeadNeckMD explains how adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in patients with head and neck cancers. Learn more: https://t.co/lR4fs22wpB #ASCO25 #hncsm

💊 Breaking science, straight from #ASCO25: #Nivolumab ➕standard chemoradiotherapy slashed risk for recurrence or death by 2⃣4⃣% in patients with resected, locally advanced #HNSCC 💡 “Tremendous” results, noted Dr. Glenn J. Hanna @HeadNeckMD @DanaFarber https://t.co/5QUhgPlDsR

Early morning press briefing at #asco25 @ASCO

🎙️ Throwback Thursday: Immunobuddies Podcast Highlight from November 2023! 🎇 🧡 Managing Immunotherapy in Organ Transplant Patients 🧡 📍 Featuring: Dr. Glenn Hanna Associate Professor, Harvard Medical School Dana-Farber Cancer Institute, Boston 🩺 A 2-part deep dive into: ✅

‼️Our paper on clinical trials for patients with salivary gland cancers is now published! 🙌80% funded by Academia. Need to attract pharma interest! 🟠50% unicenter, 80% single country. Need for ⬆️ collaboration! 🟠55% enrolled any type of histologies without stratification

At @AACR @HeadNeckMD of @DanaFarber says phase II findings are relatively encouraging for pts with advanced salivary tumors, a population with high unmet clinical need with no current approved therapies. The study looked at elraglusib + chemotherapy.

Reminder: Actuate will present data on its lead investigational drug, elraglusib, in advanced salivary gland carcinoma during a poster session at the @AACR Annual Meeting 2025, tomorrow, April 29th at 2 PM CT. For more details, visit: https://t.co/HiEtCNtiSC $ACTU #AACR25

Encouraging new data at #AACR25 on micvotabart pelidotin (next-generation ADC that targets EDB+FN). Extracellular cleavage ADCs seem to have potential. Focusing on EDB+FN overexpressed in the TME may elicit sustained anti-tumor response. @PyxisOncology

Charles Kung presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. https://t.co/4kKinsm7vF

Today, we presented new data from a Phase 3 trial of our #immunotherapy in earlier stages of head and neck cancer. These data were presented during the AACR press program. Learn more here: https://t.co/HLMo9deenh

Amazing results. Will change standard of care. Congratulations to Ravi Uppaluri (@DrUppaluri⁩), Doug Adkins, and team! ⁦@WashUMedENT⁩ ⁦@washumedicine⁩ ⁦@AHNSinfo⁩

A huge thanks to Glenn Hanna, MD, of @DanaFarber, who sat down with us during #AACR25 to discuss the use of elraglusib plus chemo and immunotherapy in salivary gland cancer! See our site for more from the meeting. @HeadNeckMD @AACR #hncsm #oncology https://t.co/3nJiUIxX6x

Dr. Glenn Hanna (@HeadNeckMD), Director of the CCTI, the early drug development program at @DanaFarber, comments on the promising data on elraglusib in advanced salivary gland carcinoma to be presented in a poster session at #AACR25. Read more: https://t.co/HiEtCNtiSC $ACTU

Actuate announced that promising data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the @AACR Annual Meeting 2025 on Tuesday, April 29th. For poster presentation details: https://t.co/HiEtCNtiSC $ACTU #AACR25

We had a fantastic time at #ESMORareCancers25 presenting our #salivaryglandcancer #research working group & a poster, in addition to catching up with colleagues from all over Europe & the US 👋👋@ERN_EURACAN @myESMO #UKSGCRWG

Thank you @DanielMaMD for the invitation to join the @MayoCancerCare #headandneck #cancer symposium. Fantastic sessions. Great to share the stage with the always entertaining @HeadNeckMD!